Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-14
1996-07-16
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514635, 514717, 514880, 514881, A61K 31415, A61K 31155, A61K 31075
Patent
active
055367429
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
THIS INVENTION relates to a composition suited to use as an anti-seborrhoeic formulation which can be for the treatment of the clinical disease seborrhoeic dermatitis in animals such as dogs.
BACKGROUND OF THE INVENTION
Seborrhoea is a chronic skin disease that is considered to be a defect in keratinization with increased scale formulation. Dandruff is a mild form. Seborrhoea is divided into three clinical forms. Seborrhoea sicca which is characterised by dry scaling of the skin. Seborrhoea oleosa is characterised by local to diffuse scaling associated with excessive sebum. Seborrhoeic dermatitis is characterised by scaling and greasiness with gross evidence of local or diffuse inflammation. There are breed predilections for Cocker Spaniels, Springer Spaniels, Basset Hounds and, in particular, the most difficult form occurs in West Highland White Terriers. It is considered to be a primary keratinization defect of genetic origin. Although some causes are known, these if found are designated secondary seborrhoeas. Primary idiopathic seborrhoeic dermatitis is currently considered to be a chronic disease that can be ameliorated but not cured.
Standard ameliorating treatments are usually shampoos containing salicylic acid, sulphur, selenium sulphide, tars and antiseptics. These give only very temporary relief from symptoms, usually for a few days at the most.
Human seborrhoeic dermatitis has recently been associated with the yeast Malassezia (Pityrosporum) ovale. Malassezia packydermatis has been reported to be associated with a dermatitis in dogs. However, dogs with the classic seborrhoeic dermatitis in West Highland Whites have been treated with ketaconazole tablets orally without producing a reliable cure. Symptoms reoccurred or worsened while on a treatment.
OBJECT OF THE INVENTION
It is an object of the invention to provide an anti-seborrhoeic formulation which is effective against seborrhoeic dermatitis achieving a therapeutic response not known before from standard treatments.
NATURE OF THE INVENTION
The invention achieves its object in provision of a composition for treatment of seborrhoeic skin disease comprising a broad spectrum anti-fungal drug and/or a topical antiseptic.
Preferably the composition is formulated for topical application and it may include a keratolytic/keratoplastic compound.
Preferably the broad spectrum anti-fungal drug is one of the imidazole/triazole group, for example miconazole.
Preferably the topical antiseptic is a phenolbiguanide type such as chlorhexidine, or tricolsan.
Preferably the keratolytic/keratoplastic compound is selenium sulphide.
Preferably the composition is provided in a shampoo base which might be any standard shampoo base and, in particular, a typical anti-dandruff shampoo base is used.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will now be described with reference to the graph of FIG. 1 which illustrates the results of a trial of a particular composition in accordance with the invention.
PREFERRED EMBODIMENTS
In tests of a composition in accordance with the invention, 41 dogs were diagnosed with seborrhoeic dermatitis. These 41 dogs contained a disproportional high number of West Highland White dogs as compared with the normal dog population. This is to be expected given the breed predisposition to this disease. A double blind randomised clinical trial was designed around two shampoo treatments. Cross over from one treatment group to the other was allowed if the first treatment failed.
The dogs were treated with either an industry standard 1% selenium sulphide shampoo (Selsun Blue or Seleen) originating from Abbots Laboratories or the following composition in accordance with the invention; a shampoo containing 0.25% selenium sulphide, 2.0% chlorhexidine and 2.0% miconazole. All ingredients are measured by weight. The response was then measured on an objective scale by looking for improvement in the clinical symptoms at two and four weeks.
FIG. 1 depicts graphically the results of the trial which indicates that the
REFERENCES:
patent: 4472421 (1984-09-01), Buchel et al.
Muller et al., Small Animal Dermatology (1989 Fourth Edition. W. B. Saunders Company, 718-726.
Kummel, Color Atlas of Small Animal Dermatology (1990) The C. V. Mosby Company, 140 and 142.
Nesbitt et al., Dermatology for the Small Animal Practitioner--exotics feline canine (1991) Veterinary Learning Systems Co., Inc. 63, 147-149.
Plant et al., Factors Associated with and Prevalence of High Malassezia Pachydermatis Numbers on Dog Skin (Sep. 15, 1992) 201(6) JAVMA, 879-882.
Power et al., Use of Etretinate for Treatment of Primary Keratinization Disorders (idiopathic seborrhea) in Cocker Spaniels, West Highland White Terriers, and Basset Hounds (Aug. 1, 1992) 201(3) JAVMA, 419-429.
Griffen et al, Primary Keratinization Disorders of Dogs (1993) Current Veterinary Dermatology, The Science and Art of Therapy Mosby-Year Book, Inc., 178-179.
Wilkinson et al., Congenital and Hereditary Dermatoses (1994) Color Atlas of Small Animal Dermatology--A Guide to Diagnosis- Second Edition. Mosby-Wolfe Publishing, 268-269.
Bond et al., Comparison of Two Shampoos for Treatment of M pachydermatis--Associated Seborrhoeic Dermatitis in Basset Hounds (1995) (36) Journal of Small Animal Practice, 99-103.
LandOfFree
Anti-seborrhoeic formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-seborrhoeic formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-seborrhoeic formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784594